Avecho Biotechnology Limited (AU:AVE) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Avecho Biotechnology Limited has announced the commencement of patient dosing in its Phase III Clinical Trial, testing a proprietary CBD soft-gel capsule for the treatment of insomnia, with recruitment across multiple Australian cities. The company is leveraging a financing arrangement with Endpoint Capital to advance funds from expected R&D tax refunds, aiding in the continuation of the trial without the immediate need for dilutive equity raising. Avecho ended the quarter with a strong cash position of A$4.8 million, having invested in R&D and received government R&D grants.
For further insights into AU:AVE stock, check out TipRanks’ Stock Analysis page.